![Kathy Dong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kathy Dong
Algemeen Directeur bij Electra Therapeutics, Inc.
Profiel
Kathy Dong is currently the President & Chief Executive Officer at Electra Therapeutics, Inc. and also serves as a Director at Neuron23, Inc. Previously, she worked as the Chief Operating Officer at Star Therapeutics, Inc. Dr. Dong holds an MBA and a doctorate from the University of New Mexico School of Medicine.
Actieve functies van Kathy Dong
Bedrijven | Functie | Begin |
---|---|---|
Neuron23, Inc.
![]() Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Directeur/Bestuurslid | 14-06-2022 |
Electra Therapeutics, Inc.
![]() Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Algemeen Directeur | 11-12-2023 |
Eerdere bekende functies van Kathy Dong
Bedrijven | Functie | Einde |
---|---|---|
Star Therapeutics, Inc.
![]() Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Operationeel Directeur | - |
Opleiding van Kathy Dong
University of New Mexico School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
Star Therapeutics, Inc.
![]() Star Therapeutics, Inc. BiotechnologyHealth Technology Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |
Neuron23, Inc.
![]() Neuron23, Inc. Miscellaneous Commercial ServicesCommercial Services Neuron23, Inc. is a clinical-stage biotechnology company based in an undisclosed location. The American company's focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The company was founded by Adam Knight and Nancy E. Stagliano has been the CEO of the company since 2019. | Commercial Services |
Electra Therapeutics, Inc.
![]() Electra Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Electra Therapeutics, Inc. is a clinical stage biotechnology company that develops therapies for the treatment of immunological diseases and cancer. The company is based in San Francisco, CA. The company's lead product candidate, ela026, is a monoclonal antibody that targets sirp on the cell surface of and t cells, and precisely depletes pathological immune cells. Electra currently has one program in clinical development and additional preclinical programs. The company was founded by Adam Rosenthal, who has been the CEO since incorporation. | Health Technology |